02
Feb

Ann Arbor, MI, biotech Esperion Therapeutics finally resolved the FDA snag standing in the way of its ambitious plans for a new cholesterol drug, clearing the company to begin late-stage trials with its potentially disruptive pill.

…read more

Source: Esperion gets out from under the FDA and speeds toward Phase III

    

0 No comments